Allergan (AGN) PT Cut To $189 At Wells Fargo After Rapastinel Misses Endpoints
Tweet Send to a Friend
Wells Fargo analyst, David Maris, reiterated his Outperform rating on shares of Allergen (NYSE: AGN) and cut his PT to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


